Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin extension study in NSCLC-cachexia
NCT01395914Phase 3Completed
- Start
- Jul 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in cancer cachexia comparing Anamorelin 100 mg with Placebo (2 arms). Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events at 12 weeks. Started Jul 2011; status: completed.
02
Drugs
anamorelin
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT01395914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01395914.